MarginsXMarginsX
Home › Markets › Health Care › BMEA

Biomea Fusion Inc. (BMEA)

BMEA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5201
-10.67% on the day
Market cap
$37.8M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBMEA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001840439
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
7.2 months
$26.4M cash at September 30, 2026
Share count, 1 year
+2.8%
2025-10-31 to 2026-10-29 · +103.5% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$196K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"There is substantial doubt about our ability to continue as a going concern, and we will require substantial additional capital to finance our operations."
10-Q 2026-11-10
Cash and burn$26.4M cash; operating cash flow -$11.0M a quarter.Report 2026-09-30
Shares outstanding72,678,080 (2026-10-29); 70,703,639 a year earlier; 35,705,786 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-09-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $196K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$6.2M-$8.4M$26.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$8.3M-$10.0M$34.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$12.4M-$11.7M$44.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed$4.6M-$13.9M$55.8MNo debt tagsNeeds four quarters10-K 2026-03-24
Q3 2025
2025-09-30
Not filed-$16.4M-$11.6M$46.6MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$20.7M-$19.2M$56.2MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$29.3M-$25.7M$35.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$29.3M-$30.0M$58.3MNo debt tagsNeeds four quarters10-K 2025-03-31

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-22
Latest annual report10-K2026-03-24
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-27

Source: SEC EDGAR submissions feed, 292 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.6%
1 month-53.8%
3 months-54.5%
Year to date-53.1%
1 year-54.9%
From 52-week high-73.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SERSerina Therapeutics Inc.$1.42+2.16%$37.7M
HYPDHyperion DeFi Inc.$2.47-4.26%$38.3M
GRCEGrace Therapeutics Inc.$1.75-3.31%$36.8M
ATHEAlterity Therapeutics Limited$1.960.00%$35.7M
VERUVeru Inc.$2.08-0.48%$35.5M
TELOTelomir Pharmaceuticals Inc.$0.4810-1.96%$35.4M
OSTXOS Therapies Incorporated$0.6807-8.63%$35.4M
ALDXAldeyra Therapeutics Inc.$0.6696+4.01%$40.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier